These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33441553)

  • 1. Engineered dual selection for directed evolution of SpCas9 PAM specificity.
    Goldberg GW; Spencer JM; Giganti DO; Camellato BR; Agmon N; Ichikawa DM; Boeke JD; Noyes MB
    Nat Commun; 2021 Jan; 12(1):349. PubMed ID: 33441553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease.
    Chen W; Zhang H; Zhang Y; Wang Y; Gan J; Ji Q
    PLoS Biol; 2019 Oct; 17(10):e3000496. PubMed ID: 31603896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous evolution of SpCas9 variants compatible with non-G PAMs.
    Miller SM; Wang T; Randolph PB; Arbab M; Shen MW; Huang TP; Matuszek Z; Newby GA; Rees HA; Liu DR
    Nat Biotechnol; 2020 Apr; 38(4):471-481. PubMed ID: 32042170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
    Hu JH; Miller SM; Geurts MH; Tang W; Chen L; Sun N; Zeina CM; Gao X; Rees HA; Lin Z; Liu DR
    Nature; 2018 Apr; 556(7699):57-63. PubMed ID: 29512652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
    Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
    Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Mechanism of D1135E-Induced Discriminated CRISPR-Cas9 PAM Recognition.
    Kang M; Zuo Z; Yin Z; Gu J
    J Chem Inf Model; 2022 Jun; 62(12):3057-3066. PubMed ID: 35666156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Plasticity of PAM Recognition by Engineered Variants of the RNA-Guided Endonuclease Cas9.
    Anders C; Bargsten K; Jinek M
    Mol Cell; 2016 Mar; 61(6):895-902. PubMed ID: 26990992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome editing in plants by engineered CRISPR-Cas9 recognizing NG PAM.
    Endo M; Mikami M; Endo A; Kaya H; Itoh T; Nishimasu H; Nureki O; Toki S
    Nat Plants; 2019 Jan; 5(1):14-17. PubMed ID: 30531939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Basis for the Altered PAM Specificities of Engineered CRISPR-Cas9.
    Hirano S; Nishimasu H; Ishitani R; Nureki O
    Mol Cell; 2016 Mar; 61(6):886-94. PubMed ID: 26990991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights into a high fidelity variant of SpCas9.
    Guo M; Ren K; Zhu Y; Tang Z; Wang Y; Zhang B; Huang Z
    Cell Res; 2019 Mar; 29(3):183-192. PubMed ID: 30664728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly efficient base editing with expanded targeting scope using SpCas9-NG in rabbits.
    Liu Z; Shan H; Chen S; Chen M; Song Y; Lai L; Li Z
    FASEB J; 2020 Jan; 34(1):588-596. PubMed ID: 31914687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The post-PAM interaction of RNA-guided spCas9 with DNA dictates its target binding and dissociation.
    Zhang Q; Wen F; Zhang S; Jin J; Bi L; Lu Y; Li M; Xi XG; Huang X; Shen B; Sun B
    Sci Adv; 2019 Nov; 5(11):eaaw9807. PubMed ID: 31763447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome editing mediated by SpCas9 variants with broad non-canonical PAM compatibility in plants.
    Li J; Xu R; Qin R; Liu X; Kong F; Wei P
    Mol Plant; 2021 Feb; 14(2):352-360. PubMed ID: 33383203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the mechanisms of PAMless DNA interrogation by SpRY-Cas9.
    Hibshman GN; Bravo JPK; Hooper MM; Dangerfield TL; Zhang H; Finkelstein IJ; Johnson KA; Taylor DW
    Nat Commun; 2024 Apr; 15(1):3663. PubMed ID: 38688943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of genetically modified mice using SpCas9-NG engineered nuclease.
    Fujii W; Ito H; Kanke T; Ikeda A; Sugiura K; Naito K
    Sci Rep; 2019 Sep; 9(1):12878. PubMed ID: 31501500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can SpRY recognize any PAM in human cells?
    Ye J; Xi H; Chen Y; Chen Q; Lu X; Lv J; Chen Y; Gu F; Zhao J
    J Zhejiang Univ Sci B; 2022 May; 23(5):382-391. PubMed ID: 35557039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient DNA interrogation of SpCas9 governed by its electrostatic interaction with DNA beyond the PAM and protospacer.
    Zhang Q; Chen Z; Wang F; Zhang S; Chen H; Gu X; Wen F; Jin J; Zhang X; Huang X; Shen B; Sun B
    Nucleic Acids Res; 2021 Dec; 49(21):12433-12444. PubMed ID: 34850124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding the Genome-Editing Toolbox with
    Nakamura A; Yamamoto H; Yano T; Hasegawa R; Makino Y; Mitsuda N; Terakawa T; Ito S; Sugano SS
    CRISPR J; 2024 Aug; 7(4):197-209. PubMed ID: 39111827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA targeting by Clostridium cellulolyticum CRISPR-Cas9 Type II-C system.
    Fedorova I; Arseniev A; Selkova P; Pobegalov G; Goryanin I; Vasileva A; Musharova O; Abramova M; Kazalov M; Zyubko T; Artamonova T; Artamonova D; Shmakov S; Khodorkovskii M; Severinov K
    Nucleic Acids Res; 2020 Feb; 48(4):2026-2034. PubMed ID: 31943070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.